16 September 2026 editorial review · Trial
ASITI-201 Phase 1 in stage 3 T1D (Queensland): review notes
These notes document the scope actually reviewed, including source-access limits. They are not independent clinical certification or a guarantee that every claim was verified.
Read the trial evidence page →Baseline trial evidence review: A–H
Outcome: No new discrepancy identified in the reviewed summary, stated design, primary endpoint and eligibility against the available registry. This is a bounded protocol comparison, not confirmation of efficacy.
Registry: ACTRN12624001043527. Primary registry detail: ANZCTR reports Phase 1, target 36, accrual 27, Part A complete and Part B recruiting; age 18–55, diagnosis within five years, specified HLA and residual C-peptide requirements. No efficacy result established.